<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37339631</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6605</ISSN><JournalIssue CitedMedium="Internet"><Volume>110</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>CGG repeat expansion in LRP12 in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1086</StartPage><EndPage>1097</EndPage><MedlinePgn>1086-1097</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajhg.2023.05.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-9297(23)00198-2</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the degeneration of motor neurons. Although repeat expansion in C9orf72 is its most common cause, the pathogenesis of ALS isn't fully clear. In this study, we show that repeat expansion in LRP12, a causative variant of oculopharyngodistal myopathy type 1 (OPDM1), is a cause of ALS. We identify CGG repeat expansion in LRP12 in five families and two simplex individuals. These ALS individuals (LRP12-ALS) have 61-100 repeats, which contrasts with most OPDM individuals with repeat expansion in LRP12 (LRP12-OPDM), who have 100-200 repeats. Phosphorylated TDP-43 is present in the cytoplasm of iPS cell-derived motor neurons (iPSMNs) in LRP12-ALS, a finding that reproduces the pathological hallmark of ALS. RNA foci are more prominent in muscle and iPSMNs in LRP12-ALS than in LRP12-OPDM. Muscleblind-like 1 aggregates are observed only in OPDM muscle. In conclusion, CGG repeat expansions in LRP12 cause ALS and OPDM, depending on the length of the repeat. Our findings provide insight into the repeat length-dependent switching of phenotypes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kume</LastName><ForeName>Kodai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Molecular Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurashige</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muguruma</LastName><ForeName>Keiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of iPS Cell Applied Medicine, Graduate School of Medicine, Kansai Medical University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morino</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tada</LastName><ForeName>Yui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Molecular Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kikumoto</LastName><ForeName>Mai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Tatsuo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Genetics and Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akutsu</LastName><ForeName>Silvia Natsuko</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Department of Genetics and Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuda</LastName><ForeName>Yukiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Molecular Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuura</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Genetics and Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamori</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishiyama</LastName><ForeName>Ayumi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Miyagi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumi</LastName><ForeName>Rumiko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Miyagi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niihori</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics, Tohoku University Graduate School of Medicine, Miyagi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogasawara</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Research, National Institute of Neuroscience, National Centre of Neurology and Psychiatry, National Centre Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eura</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Research, National Institute of Neuroscience, National Centre of Neurology and Psychiatry, National Centre Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Tamaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokomura</LastName><ForeName>Mamoru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakayama</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Wakayama Medical University, Wakayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Hidefumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Wakayama Medical University, Wakayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Masataka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kansai Medical University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Kayoko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riku</LastName><ForeName>Yuichi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruyama</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics, Tohoku University Graduate School of Medicine, Miyagi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishino</LastName><ForeName>Ichizo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Research, National Institute of Neuroscience, National Centre of Neurology and Psychiatry, National Centre Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumi</LastName><ForeName>Yuishin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine, Miyagi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawakami</LastName><ForeName>Hideshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. Electronic address: hkawakam@hiroshima-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C483993">LRP12 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026503">Low Density Lipoprotein Receptor-Related Protein-1</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C563508">Oculopharyngodistal Myopathy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009136" MajorTopicYN="Y">Muscular Dystrophies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026503" MajorTopicYN="N">Low Density Lipoprotein Receptor-Related Protein-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">CGG repeat expansion</Keyword><Keyword MajorTopicYN="N">LRP12</Keyword><Keyword MajorTopicYN="N">OPDM</Keyword><Keyword MajorTopicYN="N">RNA foci</Keyword><Keyword MajorTopicYN="N">iPSCs</Keyword><Keyword MajorTopicYN="N">motor neuron</Keyword><Keyword MajorTopicYN="N">pTDP-43</Keyword><Keyword MajorTopicYN="N">repeat disease</Keyword><Keyword MajorTopicYN="N">skeletal muscle</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>21</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>20</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37339631</ArticleId><ArticleId IdType="pmc">PMC10357476</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2023.05.014</ArticleId><ArticleId IdType="pii">S0002-9297(23)00198-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Love S., Greenfield J.G. 9th edition. CRC Press; 2015. Greenfield&#x2019;s Neuropathology.</Citation></Reference><Reference><Citation>Goutman S.A., Hardiman O., Al-Chalabi A., Chi&#xf3; A., Savelieff M.G., Kiernan M.C., Feldman E.L. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21:480&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9513753</ArticleId><ArticleId IdType="pubmed">35334233</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden A.C., Kim H.J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., Armakola M., Geser F., Greene R., Lu M.M., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Sim&#xf3;n-S&#xe1;nchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann H., Hornburg D., Czuppa M., Bader J., Michaelsen M., Farny D., Arzberger T., Mann M., Meissner F., Edbauer D. Proteomics and C9orf72 neuropathology identify ribosomes as poly-GR/PR interactors driving toxicity. Life Sci. Alliance. 2018;1:e201800070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6238541</ArticleId><ArticleId IdType="pubmed">30456350</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Weng S.-M., Arzberger T., May S., Rentzsch K., Kremmer E., Schmid B., Kretzschmar H.A., Cruts M., Van Broeckhoven C., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiura H., Shibata S., Yoshimura J., Suzuki Y., Qu W., Doi K., Almansour M.A., Kikuchi J.K., Taira M., Mitsui J., et al. Noncoding CGG repeat expansions in neuronal intranuclear inclusion disease, oculopharyngodistal myopathy and an overlapping disease. Nat. Genet. 2019;51:1222&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pubmed">31332380</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J., Yu J., Li P., Luan X., Cao L., Zhao J., Yu M., Zhang W., Lv H., Xie Z., et al. Expansion of GGC repeat in GIPC1 is associated with oculopharyngodistal myopathy. Am. J. Hum. Genet. 2020;106:793&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273532</ArticleId><ArticleId IdType="pubmed">32413282</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogasawara M., Iida A., Kumutpongpanich T., Ozaki A., Oya Y., Konishi H., Nakamura A., Abe R., Takai H., Hanajima R., et al. CGG expansion in NOTCH2NLC is associated with oculopharyngodistal myopathy with neurological manifestations. Acta Neuropathol. Commun. 2020;8:204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7690190</ArticleId><ArticleId IdType="pubmed">33239111</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J., Deng J., Guo X., Shan J., Luan X., Cao L., Zhao J., Yu M., Zhang W., Lv H., et al. The GGC repeat expansion in NOTCH2NLC is associated with oculopharyngodistal myopathy type 3. Brain. 2021;144:1819&#x2013;1832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8320266</ArticleId><ArticleId IdType="pubmed">33693509</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J., Shan J., Yu M., Di L., Xie Z., Zhang W., Lv H., Meng L., Zheng Y., Zhao Y., et al. The CGG repeat expansion in RILPL1 is associated with oculopharyngodistal myopathy type 4. Am. J. Hum. Genet. 2022;109:533&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8948162</ArticleId><ArticleId IdType="pubmed">35148830</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Y.-H., Yang K., Du G.-Q., Chen Y.-K., Cao C.-Y., Qiu Y.-S., He J., Lv H.-D., Qu Q.-Q., Chen J.-N., et al. GGC repeat expansion of RILPL1 is associated with oculopharyngodistal myopathy. Ann. Neurol. 2022;92:512&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">35700120</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazawa H., Kato M., Awata T., Kohda M., Iwasa H., Koyama N., Tanaka T., Kyo S., Okazaki Y., Hagiwara K. Homozygosity haplotype allows a genomewide search for the autosomal segments shared among patients. Am. J. Hum. Genet. 2007;80:1090&#x2013;1102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1867097</ArticleId><ArticleId IdType="pubmed">17503327</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudbjartsson D.F., Jonasson K., Frigge M.L., Kong A. Allegro, a new computer program for multipoint linkage analysis. Nat. Genet. 2000;25:12&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10802644</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda Y., Morino H., Miyamoto R., Kurashige T., Kume K., Mizuno N., Kanaya Y., Tada Y., Ohsawa R., Yokota K., et al. Biallelic mutation of HSD17B4 induces middle age-onset spinocerebellar ataxia. Neurol. Genet. 2020;6:e396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6975179</ArticleId><ArticleId IdType="pubmed">32042923</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng P.C., Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11:863&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311071</ArticleId><ArticleId IdType="pubmed">11337480</ArticleId></ArticleIdList></Reference><Reference><Citation>Adzhubei I.A., Schmidt S., Peshkin L., Ramensky V.E., Gerasimova A., Bork P., Kondrashov A.S., Sunyaev S.R. A method and server for predicting damaging missense mutations. Nat. Methods. 2010;7:248&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855889</ArticleId><ArticleId IdType="pubmed">20354512</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzsch P., Witten D., Cooper G.M., Shendure J., Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47:D886&#x2013;D894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323892</ArticleId><ArticleId IdType="pubmed">30371827</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuhashi S., Frith M.C., Mizuguchi T., Miyatake S., Toyota T., Adachi H., Oma Y., Kino Y., Mitsuhashi H., Matsumoto N. Tandem-genotypes: robust detection of tandem repeat expansions from long DNA reads. Genome Biol. 2019;20:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425644</ArticleId><ArticleId IdType="pubmed">30890163</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster W., Stovner E.B., Strazisar M. Methplotlib: analysis of modified nucleotides from nanopore sequencing. Bioinformatics. 2020;36:3236&#x2013;3238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7214038</ArticleId><ArticleId IdType="pubmed">32053166</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K., Matsumura Y., Sato Y., Okada A., Morizane A., Okamoto S., Hong H., Nakagawa M., Tanabe K., Tezuka K.i., et al. A more efficient method to generate integration-free human iPS cells. Nat. Methods. 2011;8:409&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">21460823</ArticleId></ArticleIdList></Reference><Reference><Citation>Okita K., Yamakawa T., Matsumura Y., Sato Y., Amano N., Watanabe A., Goshima N., Yamanaka S. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cell. 2013;31:458&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">23193063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida Y., Kawakami H., Kitajima H., Nishiyama A., Sasai Y., Inoue H., Muguruma K. Vulnerability of Purkinje cells generated from spinocerebellar ataxia type 6 patient-derived iPSCs. Cell Rep. 2016;17:1482&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pubmed">27806289</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacoste A., Berenshteyn F., Brivanlou A.H. An efficient and reversible transposable system for gene delivery and lineage-specific differentiation in human embryonic stem cells. Cell Stem Cell. 2009;5:332&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">19733544</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santis R., Garone M.G., Pagani F., de Turris V., Di Angelantonio S., Rosa A. Direct conversion of human pluripotent stem cells into cranial motor neurons using a piggyBac vector. Stem Cell Res. 2018;29:189&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">29729503</ArticleId></ArticleIdList></Reference><Reference><Citation>Garone M.G., de Turris V., Soloperto A., Brighi C., De Santis R., Pagani F., Di Angelantonio S., Rosa A. Conversion of human induced pluripotent stem cells (iPSCs) into functional spinal and cranial motor neurons using piggyBac vectors. J.&#xa0;Vis. Exp. 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31107442</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa A., Papaioannou M.D., Krzyspiak J.E., Brivanlou A.H. miR-373 is regulated by TGF&#x3b2; signaling and promotes mesendoderm differentiation in human embryonic stem cells. Dev. Biol. 2014;391:81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4081558</ArticleId><ArticleId IdType="pubmed">24709321</ArticleId></ArticleIdList></Reference><Reference><Citation>Muguruma K., Nishiyama A., Kawakami H., Hashimoto K., Sasai Y. Self-organization of polarized cerebellar tissue in 3D culture of human pluripotent stem cells. Cell Rep. 2015;10:537&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">25640179</ArticleId></ArticleIdList></Reference><Reference><Citation>Muguruma K., Nishiyama A., Ono Y., Miyawaki H., Mizuhara E., Hori S., Kakizuka A., Obata K., Yanagawa Y., Hirano T., Sasai Y. Ontogeny-recapitulating generation and tissue integration of ES cell-derived Purkinje cells. Nat. Neurosci. 2010;13:1171&#x2013;1180.</Citation><ArticleIdList><ArticleId IdType="pubmed">20835252</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurashige T., Morino H., Murao T., Izumi Y., Sugiura T., Kuraoka K., Kawakami H., Torii T., Maruyama H. TDP-43 Accumulation within intramuscular nerve bundles of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79:693&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127711</ArticleId><ArticleId IdType="pubmed">35604654</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L., World Federation of Neurology Research Group on Motor Neuron Diseases El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M., Dengler R., Eisen A., England J.D., Kaji R., Kimura J., Mills K., Mitsumoto H., Nodera H., Shefner J., Swash M. Electrodiagnostic criteria for diagnosis of ALS. Clin. Neurophysiol. 2008;119:497&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Mackenzie I.R.A. Review: neuropathology of non-tau frontotemporal lobar degeneration. Neuropathol. Appl. Neurobiol. 2019;45:19&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30357887</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa N., Kitaoka S., Tsukita K., Naitoh M., Takahashi K., Yamamoto T., Adachi F., Kondo T., Okita K., Asaka I., et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 2012;4:145ra104. doi: 10.1126/scitranslmed.3004052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3004052</ArticleId><ArticleId IdType="pubmed">22855461</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C., Rau F., Liu Y., Tassone F., Hukema R.K., Gattoni R., Schneider A., Richard S., Willemsen R., Elliott D.J., et al. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J. 2010;29:1248&#x2013;1261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2857464</ArticleId><ArticleId IdType="pubmed">20186122</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumutpongpanich T., Ogasawara M., Ozaki A., Ishiura H., Tsuji S., Minami N., Hayashi S., Noguchi S., Iida A., Nishino I., et al. Clinicopathologic features of oculopharyngodistal myopathy with LRP12 CGG repeat expansions compared with other oculopharyngodistal myopathy subtypes. JAMA Neurol. 2021;78:853&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8164150</ArticleId><ArticleId IdType="pubmed">34047774</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer E.J., Pritchard M., Lynch M., Yu S., Holman K., Baker E., Warren S.T., Schlessinger D., Sutherland G.R., Richards R.I. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science (New York, N.Y.) 1991;252:1711&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pubmed">1675488</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerman R.J., Leehey M., Heinrichs W., Tassone F., Wilson R., Hills J., Grigsby J., Gage B., Hagerman P.J. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology. 2001;57:127&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagerman R., Hagerman P. Fragile X-associated tremor/ataxia syndrome: pathophysiology and management. Curr. Opin. Neurol. 2021;34:541&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412174</ArticleId><ArticleId IdType="pubmed">33990099</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobile V., Pucci C., Chiurazzi P., Neri G., Tabolacci E. DNA methylation, mechanisms of FMR1 inactivation and therapeutic perspectives for fragile X syndrome. Biomolecules. 2021;11:296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7920310</ArticleId><ArticleId IdType="pubmed">33669384</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez C.M., Wright S.E., Kearse M.G., Haenfler J.M., Flores B.N., Liu Y., Ifrim M.F., Glineburg M.R., Krans A., Jafar-Nejad P., et al. A native function for RAN translation and CGG repeats in regulating fragile X protein synthesis. Nat. Neurosci. 2020;23:386&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7668390</ArticleId><ArticleId IdType="pubmed">32066985</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckers J., Tharkeshwar A.K., Van Damme P. C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy. 2021;17:3306&#x2013;3322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632097</ArticleId><ArticleId IdType="pubmed">33632058</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito R., Shimizu H., Miura T., Hara N., Mezaki N., Higuchi Y., Miyashita A., Kawachi I., Sanpei K., Honma Y., et al. Oculopharyngodistal myopathy with coexisting histology of systemic neuronal intranuclear inclusion disease: Clinicopathologic features of an autopsied patient harboring CGG repeat expansions in LRP12. Acta Neuropathol. Commun. 2020;8:75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7268649</ArticleId><ArticleId IdType="pubmed">32493488</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>